Chronic hepatitis B and non‐alcoholic fatty liver disease: Conspirators or competitors?

Despite the widespread use of vaccines and antiviral drugs, approximately 350‐400 million patients with chronic hepatitis B (CHB) remain worldwide, who carry high risk of cirrhosis and liver carcinoma. Moreover, owing to improvements in global living standards and lifestyle changes, non‐alcoholic fa...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2020-03, Vol.40 (3), p.496-508
Main Authors: Zhang, Jianbin, Lin, Shuangzhe, Jiang, Daixi, Li, Mengting, Chen, Yuanwen, Li, Jun, Fan, Jiangao
Format: Article
Language:English
Subjects:
animal model
Animal models
Antiviral agents
chronic hepatitis B
Cirrhosis
Coexistence
Fatty liver
genetic susceptibility
Hepatitis
Hepatitis B
innate immunity
Interferon
Liver
Liver cirrhosis
Liver diseases
metabolism
non‐alcoholic fatty liver disease
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the widespread use of vaccines and antiviral drugs, approximately 350‐400 million patients with chronic hepatitis B (CHB) remain worldwide, who carry high risk of cirrhosis and liver carcinoma. Moreover, owing to improvements in global living standards and lifestyle changes, non‐alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease. Coexistence of NAFLD and CHB is commonly observed, especially in Asian CHB populations; however, little is known regarding the relationship between these two diseases as comorbidities. In this review, we summarize recent advances in clinical and basic researches related to the underlying mutual interactions, as well as potential animal models to facilitate further investigation.
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.14369